Abstract
Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses (<5, 5-11, 12-21 years) in 177 pediatric patients hospitalized with severe acute COVID-19, acute MIS-C, and in convalescent samples of outpatients with mild COVID-19 during 2020 and early 2021. Across all patients, less than 10% show neutralizing antibody titers against Omicron. Children <5 years of age hospitalized with severe acute COVID-19 have lower neutralizing antibodies to SARS-CoV-2 variants compared with patients >5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.
【초록키워드】 COVID-19, neutralizing antibody, SARS-CoV-2, vaccination, Hospitalized, Neutralizing antibodies, antibody, neutralization, SARS-COV-2 infection, pediatric, children, variant, SARS-CoV-2 variant, Delta, Transmission, outcome, omicron, Omicron variants, variants, MIS-C, Cohort, SARS-CoV-2 variants, cross-neutralization, Patient, Re-infection, Gamma, Mild, Alpha, Beta, age, outpatients, neutralizing capacity, convalescent, patients, Antibody titers, Neutralizing antibody titer, Outpatient, Analysis, neutralization capacity, Support, Pediatric patient, neutralizing antibody titers, acute COVID-19, neutralization titer, clinical disease, evaluated, less, demonstrated, virus-neutralizing, expected, 【제목키워드】 COVID-19, Immunity, variant, MIS-C, Pediatric patient, the SARS-CoV-2,